Pharmacokinetics or PK is an important branch of pharmacology that investigates the fate of substances mainly drug compounds in the body that have been administered externally. PK studies include the study of Absorption, Distribution, Metabolism and Excretion (ADME) of new pharmaceutical compounds as these four criteria influence the drug levels and kinetics of drug exposure to the tissues and hence influence the performance and pharmacological activity of the compound as a drug. PK analysis for the selection of new drug candidates can be carried out in a number of ways that include preclinical bioanalytical methods and compartmental or non-compartmental analysis. These techniques are used to generate information for the construction of plasma concentration versus time profiles that can be used to select appropriate new drug candidates. The primary reason cited for failure of most new drug candidates during clinical studies is the lack of an appropriate PK profile.
Preclinical bioanalytical methods can be used to construct plasma concentration versus time profiles using chemical techniques that measure the concentration of the drug candidate in the biological matrix which is most often plasma. The preclinical bioanalytical techniques need to be sensitive and selective to generate an accurate PK profile as the selection of new drug candidates is dependent on such profiles. Drug candidates that exhibit an appropriate PK profile are selected as lead compounds because these candidates should achieve the desired pharmacological action with minimal side effects during clinical trials. NoAb BioDiscoveries, one of North America's leading discovery services provider, offers preclinical bioanalytical services to its clients ensuring that they select the best leads for further clinical development. The organization also offers specialized and proprietary services for in vivo PK studies, in vitro ADME profiling and gene expression assays. Detailed information on these services can be found at www.noabbiodiscoveries.com.
The team of highly trained and experienced scientists at NoAb BioDiscoveries designs the best strategies and protocols for any drug discovery needs. Using innovation to develop advanced research tools, pharmacokinetic properties of new drug candidates can be better characterized and lead selection of viable clinical candidates is optimized. The knowledge and expertise of these scientists allows NoAb BioDiscoveries to provide a wide range of preclinical bioanalytical support services to its clients. These services include:
" Method development, qualification and sample analysis in various biological matrices.
" PK sample screening including cassette dosed animals and brain penetration studies.
" Stability sample analysis (compound, plasma, metabolic etc.).
" Metabolite profiling and identification studies.
" Determination of biogenic amines in biological fluids using HPLC with electrochemical detection.
The broad range of preclinical bioanalytical support and the innovative technologies from NoAb BioDiscoveries help to shape and optimize the drug discovery process by focusing on lead selection and optimization. This is accomplished in accelerated timelines that ensure your success. NoAb BioDiscoveries strives to continue providing premier drug discovery services to its clients by using innovation to improve the future of drug discovery research. You as the client can reduce the cost associated with the identification of new drug candidates as well as the cost and time to market a new drug while maximizing your success when you choose NoAb BioDiscoveries as your trusted partner in the process! Visit www.noabbiodiscoveries.com and discover quality, efficient and timely drug discovery services!
